Lyell Immunopharma is a South San Francisco-based, publicly traded cell therapy company (LYEL). Their T cell reprogramming technology focuses on the mastery of T cells to cure patients with solid tumors. They apply proprietary genetic and epigenetic reprogramming technology platforms to address barriers present in solid tumors in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
